Levorol

Levomepromazine, the active ingredient in Levorol, is a phenothiazine antipsychotic presented as an oral tablet for oral use. It treats schizophrenia, severe agitation, nausea and vomiting, and is used in palliative care for symptom control. It works by blocking dopamine D2 receptors as well as histamine, muscarinic and alpha‑adrenergic receptors.

GNH USA supplies Levorol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomepromazine is used in the management of psychotic disorders and related conditions.

- Schizophrenia: reduces delusions, hallucinations and other psychotic symptoms. - Severe agitation: calms acute agitation and aggressive behaviour. - Nausea and vomiting: controls refractory nausea, especially in oncology or palliative settings. - Palliative care symptom control: alleviates anxiety, pain‑related insomnia and refractory nausea.

Levomepromazine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: sedation and fatigue. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Orthostatic hypotension: dizziness upon standing.

Serious or Rare Side Effects: - Extrapyramidal symptoms: muscle rigidity, tremor, or dystonia. - Neuroleptic malignant syndrome: fever, muscle rigidity, autonomic instability. - Tardive dyskinesia: involuntary movements after prolonged use. - Cardiac arrhythmias: QT prolongation or other rhythm disturbances.

When prescribing levomepromazine, clinicians should consider several safety measures.

- Monitor blood pressure: watch for orthostatic hypotension especially at treatment start. - Assess cardiac risk: obtain ECG if the patient has known QT‑prolongation. - Evaluate hepatic function: dose adjustment may be needed in severe liver impairment. - Use caution in the elderly: increased sensitivity to sedative and anticholinergic effects. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal or rebound agitation. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Levomepromazine interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Other CNS depressants: may enhance sedation and respiratory depression. - Anticholinergic drugs: increase risk of severe anticholinergic toxicity. - QT‑prolonging agents: additive risk of cardiac arrhythmias. - MAO inhibitors: can cause unpredictable hypotension and sedation.

Moderate Interactions (Monitor Closely): - Antihypertensives: may potentiate orthostatic hypotension. - Antidiabetic agents: possible alteration of glucose control. - CYP450 inhibitors/inducers: may affect levomepromazine plasma levels.